Table 1.
Pediatric CureGN Subjects
| Median (IQR) or n (%)a | Overall (n=761) | MCD (n=283) | FSGS (n=177) | MN (n=36) | IgAN (n=265) |
|---|---|---|---|---|---|
| Age at consent, y | 11 (7–15) | 8 (6–12) | 13 (8–16) | 15 (12–17) | 12 (9–15) |
| Disease duration (mo since diagnosis) | 16 (5–37) | 27 (10–51) | 14 (6–36) | 6 (2–22) | 11 (3–28) |
| Racec | |||||
| White | 510 (71) | 171 (65) | 98 (58) | 21 (64) | 220 (87) |
| Black | 132 (18) | 59 (22) | 54 (32) | 9 (27) | 10 (4) |
| Asian | 43 (6) | 21 (8) | 6 (4) | 1 (3) | 15 (6) |
| Other | 34 (5) | 13 (5) | 10 (6) | 2 (6) | 9 (4) |
| Hispanic/Latinob | 94 (12) | 35 (12) | 20 (11) | 8 (22) | 31 (12) |
| Male | 449 (59) | 174 (61) | 95 (54) | 16 (44) | 164 (62) |
| Disease classification | |||||
| Steroid/multi‐drug‐resistant | 134 (18) | 56 (20) | 59 (33) | 8 (22) | 11 (4) |
| Steroid sensitive | 256 (34) | 163 (58) | 41 (23) | 5 (14) | 47 (18) |
| Untreated | 101 (13) | 22 (8) | 28 (16) | 5 (14) | 46 (17) |
| Unknown/not applicable | 270 (35) | 42 (15) | 49 (28) | 18 (50) | 161 (61) |
| eGFR, mL/min per 1.73 m²c | 103 (86–124) | 113 (94–134) | 93 (69–114) | 103 (89–129) | 100 (86–119) |
| Serum albumin, g/dLd | 3.8 (3.0–4.2) | 3.7 (2.8–4.2) | 3.6 (2.6–4.2) | 3.2 (2.2–4.0) | 4.0 (3.6–4.2) |
| UPCRd | 0.5 (0.1–2.4) | 0.2 (0.1–2.6) | 1.2 (0.2–3.9) | 2.0 (0.9–7.0) | 0.4 (0.2–1.2) |
| Birth weight, kgd | 3.3 (3.0–3.7) | 3.3 (2.9–3.7) | 3.4 (2.9–3.7) | 3.3 (3.0–3.5) | 3.4 (3.1–3.7) |
CureGN indicates Cure Glomerulonephropathy Network; EGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IQR, interquartile range; MCD, minimal change disease; MN, membranous nephropathy; UPCR, urine protein‐to‐creatinine ratio (measured on 24–hour urine, first morning void, or spot/random urine in hierarchy as available).
a
Percent reported among nonmissing observations.
b
≤1% missing.
c
5% to 10% missing.
d
10% to 20% missing.